Yahoo Finance

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis ...
Hosted on MSN

Arvinas Unveils Promising Preclinical Data for ARV-806

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Arvinas Holding Company ( (ARVN)) has ...
Business Insider

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
Yahoo Finance

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International ...

NEW HAVEN, Conn., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...
News Medical

New discovery reshapes understanding of how brain inflammation arises in Alzheimer's disease

Researchers at the University of California, Irvine, have uncovered an unexpected molecular partnership that reshapes scientists' understanding of how brain inflammation arises in Alzheimer's disease.